NEW YORK, Oct 27 — Pfizer reported lower third-quarter profits today as Covid-19 dented demand for some medicines from patients whose regular health care patterns were disrupted.

The drugmaker, which is working on clinical trials for a coronavirus vaccine, reported a 71 per cent drop in profit to US$2.2 billion (RM9.2 billion). The year-ago period included a large gain connected to a transaction.

Revenues dipped four per cent to US$12.1 billion, missing analyst estimates.

Advertisement

Pfizer estimated a revenue hit of US$500 million connected to Covid-19 due to lower pharma demand in China and fewer wellness visits from patients in the US.

The company saw an 11 per cent drop in its hospital business in emerging markets, primarily due to fewer elective surgeries in China and shorter in-patient hospital stays in the country.

This effect was partially offset by increased demand for the Prevnar-13 vaccine for pneumonia “resulting from greater vaccine awareness for respiratory illnesses,” the company said.

Advertisement

Pfizer also cited strong performance in its biopharma business due to good sales for cancer drug Ibrance, anticoagulant Eliquis and other medications.

Pfizer said its Phase 3 Covid-19 trial had enrolled more than 40,000 participants, with nearly 36,000 having received their second vaccination as of yesterday.

Shares rose 0.7 per cent to US$38.20 in pre-market trading. — AFP